Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study.

S, Huber; C, Schwentner; D, Taeger; B, Pesch; M, Nasterlack; G, Leng; T, Mayer; K, Gawrych; N, Bonberg; M, Pelster; G, Johnen; H, Bontrup; H, Wellhäusser; HG, Bierfreund; C, Wiens; C, Bayer; F, Eberle; B, Scheuermann; M, Kluckert; G, Feil; T, Brüning; A, Stenzl

doi:10.1111/j.1464-410x.2011.10883.x

Public

Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study.

Shared by NobleBlocks on Feb 7, 2012 • 12:00 AM UTC

Authors:

Huber S

Schwentner C

Taeger D

Abstract

Unlabelled What's known on the subject? and What does the study add? The prognosis of bladder cancer significantly depends on tumour stage and time of diagnosis so early diagnosis is desirable to decrease mortality and treatment costs. The NMP22 test is approved for clinical application by the Food ...

Discussions